Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Partial neuromuscular blockade for lung- and diaphragm-protective ventilation in ICU patients
NL-OMON50261Phase 4Recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rocuronium in acute respiratory decompensation (2 arms), sponsored by Vrije University Medical Center. Primary endpoints: Feasibility to establish and maintain lung-protective ventilation for 24 hours, Percentage of breaths with tidal volume below target and 9 more. Started Sep 2018; status: recruiting.
02
Drugs
rocuronium
03
Conditions
acute respiratory decompensation
Beyond the preview
Go deeper on NL-OMON50261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50261.